When Your Sponsor Restructures Mid-Trial, Sites Pay the Operational Price
Coherus cut 30% of staff; Gyre laid off post-acquisition. Sites lose study contacts, amendments stall, and monitoring gaps widen....
Coherus cut 30% of staff; Gyre laid off post-acquisition. Sites lose study contacts, amendments stall, and monitoring gaps widen....
A new pilot shows early diversity planning cuts mid-trial amendments, here's what that means for site selection, IRT setup,...
PPMI's RBD and hyposmia enrollment strategy yields 94% CSF alpha-synuclein positivity, here's what that means for site screening workflows...
WCG's new Activation Intelligence tool claims to cut 20+ hours of rework per study launch by catching document conflicts...
AI can generate 100x more drug candidates, but trials still need real patients. The bottleneck has shifted, and most...
FDA's September 2026 adcomm recruitment push signals shifts in protocol feedback loops that sponsor clinops and sites can't afford...
An intra-arterial alteplase trial changed its primary outcome at month 12 after 283 enrollments. Here's the clinops reality of...
Mayo Test Drive completed at 97.5% across MCI, mild, and moderate dementia patients, here's what that means for Alzheimer's...
Early trial termination once signaled collapse. Now it signals design sophistication, and regulators, sponsors, and CROs need a new...
Boston Scientific's August 2026 cyberattack knocked out global IT and shipping. Here's what that means for sites running active...